Zacks: Brokerages Expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Will Post Earnings of $0.27 Per Share

Equities research analysts expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to post $0.27 earnings per share for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for Neurocrine Biosciences’ earnings. The highest EPS estimate is $0.64 and the lowest is $0.02. Neurocrine Biosciences reported earnings of ($0.07) per share in the same quarter last year, which would suggest a positive year over year growth rate of 485.7%. The business is expected to announce its next quarterly earnings report on Tuesday, July 30th.

On average, analysts expect that Neurocrine Biosciences will report full-year earnings of ($0.08) per share for the current financial year, with EPS estimates ranging from ($0.56) to $0.82. For the next financial year, analysts expect that the business will report earnings of $3.01 per share, with EPS estimates ranging from $2.15 to $4.22. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that cover Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Monday, April 29th. The company reported ($1.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.07). Neurocrine Biosciences had a negative return on equity of 9.14% and a negative net margin of 7.56%. The business had revenue of $138.40 million during the quarter, compared to analysts’ expectations of $136.77 million. During the same quarter in the prior year, the firm earned ($0.47) EPS. The firm’s revenue for the quarter was up 94.7% compared to the same quarter last year.

A number of analysts recently commented on NBIX shares. Zacks Investment Research upgraded Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating and set a $105.00 price objective for the company in a research report on Wednesday, April 10th. Evercore ISI started coverage on Neurocrine Biosciences in a research report on Thursday, April 11th. They set an “outperform” rating for the company. Barclays reiterated a “buy” rating and set a $110.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, March 29th. ValuEngine cut Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, April 15th. Finally, Guggenheim started coverage on Neurocrine Biosciences in a research report on Tuesday, June 4th. They set a “neutral” rating and a $88.00 price objective for the company. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $102.16.

In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 66,667 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $80.13, for a total transaction of $5,342,026.71. Following the completion of the sale, the insider now owns 164,415 shares of the company’s stock, valued at $13,174,573.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Haig P. Bozigian sold 34,547 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $75.51, for a total value of $2,608,643.97. The disclosure for this sale can be found here. Insiders have sold 142,732 shares of company stock valued at $11,388,472 in the last three months. 4.30% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in NBIX. Nordea Investment Management AB lifted its position in shares of Neurocrine Biosciences by 1.2% in the first quarter. Nordea Investment Management AB now owns 38,996 shares of the company’s stock worth $3,435,000 after buying an additional 465 shares in the last quarter. BlueMountain Capital Management LLC raised its position in Neurocrine Biosciences by 314.7% during the first quarter. BlueMountain Capital Management LLC now owns 63,570 shares of the company’s stock valued at $5,601,000 after purchasing an additional 48,240 shares during the period. Kore Private Wealth LLC purchased a new stake in Neurocrine Biosciences during the first quarter valued at approximately $29,000. PointState Capital LP purchased a new stake in Neurocrine Biosciences during the first quarter valued at approximately $581,000. Finally, M&T Bank Corp raised its position in Neurocrine Biosciences by 7.8% during the first quarter. M&T Bank Corp now owns 3,224 shares of the company’s stock valued at $285,000 after purchasing an additional 232 shares during the period. 96.14% of the stock is owned by institutional investors and hedge funds.

Shares of NBIX stock traded down $0.16 during mid-day trading on Tuesday, hitting $83.92. The company’s stock had a trading volume of 509,256 shares, compared to its average volume of 645,076. Neurocrine Biosciences has a 52-week low of $64.72 and a 52-week high of $126.98. The company has a debt-to-equity ratio of 0.96, a current ratio of 8.79 and a quick ratio of 8.61. The stock has a market capitalization of $7.66 billion, a P/E ratio of 381.45 and a beta of 1.46.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Read More: Dividend Aristocrat Index

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.